WuXi AppTec Keeps Bull on 3Q Earnings Beat -- Market Talk

Dow Jones10-28

0402 GMT - WuXi AppTec keeps its bull at Nomura after its 3Q profit beat analysts' consensus estimate. The Chinese pharmaceutical services company raised its 2025 revenue and plans to spend less on capital expenditure, analyst Jialin Zhang says in a note. The company also agreed to sell its Chinese clinical research services unit, he says. The analyst raised his 2025 and 2026 earnings projections by 33.5% and 33.3%, respectively, to reflect factors such as enhanced efficiency and the unit disposal. Nomura reaffirms its buy rating and raises its target on WuXi AppTec's Hong Kong stock to HK$130.63 from HK$102.77. Nomura also raises its target on its Shanghai-listed shares to CNY118.83 from CNY93.49. Shares were last at HK$114.30 in Hong Kong and CNY105.73 in China. (megan.cheah@wsj.com)

(END) Dow Jones Newswires

October 28, 2025 00:02 ET (04:02 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2578760091?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-28 12:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578760091","market":"sg","top_or_hot":-1,"title":"WuXi AppTec Keeps Bull on 3Q Earnings Beat -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0402 GMT - WuXi AppTec keeps its bull at Nomura after its 3Q profit beat analysts' consensus estimate. The Chinese pharmaceutical services company raised its 2025 revenue and plans to spend less on capital expenditure, analyst Jialin Zhang says in a note. The company also agreed to sell its Chinese clinical research services unit, he says. The analyst raised his 2025 and 2026 earnings projections by 33.5% and 33.3%, respectively, to reflect factors such as enhanced efficiency and the unit disposal. Nomura reaffirms its buy rating and raises its target on WuXi AppTec's Hong Kong stock to HK$130.63 from HK$102.77. Nomura also raises its target on its Shanghai-listed shares to CNY118.83 from CNY93.49. Shares were last at HK$114.30 in Hong Kong and CNY105.73 in China. (megan.cheah@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 28, 2025 00:02 ET (04:02 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>WuXi AppTec Keeps Bull on 3Q Earnings Beat -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWuXi AppTec Keeps Bull on 3Q Earnings Beat -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-28 12:02</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0402 GMT - WuXi AppTec keeps its bull at Nomura after its 3Q profit beat analysts' consensus estimate. The Chinese pharmaceutical services company raised its 2025 revenue and plans to spend less on capital expenditure, analyst Jialin Zhang says in a note. The company also agreed to sell its Chinese clinical research services unit, he says. The analyst raised his 2025 and 2026 earnings projections by 33.5% and 33.3%, respectively, to reflect factors such as enhanced efficiency and the unit disposal. Nomura reaffirms its buy rating and raises its target on WuXi AppTec's Hong Kong stock to HK$130.63 from HK$102.77. Nomura also raises its target on its Shanghai-listed shares to CNY118.83 from CNY93.49. Shares were last at HK$114.30 in Hong Kong and CNY105.73 in China. (megan.cheah@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 28, 2025 00:02 ET (04:02 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1934453819.USD","symbol_name":"AB CHINA A SHARES EQUITY PORTFOLIO \"A\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2578760091","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578760091","pubTimestamp":1761624120,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0402 GMT - WuXi AppTec keeps its bull at Nomura after its 3Q profit beat analysts' consensus estimate. The Chinese pharmaceutical services company raised its 2025 revenue and plans to spend less on capital expenditure, analyst Jialin Zhang says in a note. The company also agreed to sell its Chinese clinical research services unit, he says. The analyst raised his 2025 and 2026 earnings projections by 33.5% and 33.3%, respectively, to reflect factors such as enhanced efficiency and the unit disposal. Nomura reaffirms its buy rating and raises its target on WuXi AppTec's Hong Kong stock to HK$130.63 from HK$102.77. Nomura also raises its target on its Shanghai-listed shares to CNY118.83 from CNY93.49. Shares were last at HK$114.30 in Hong Kong and CNY105.73 in China. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"603259":"药明康德","LU1934453819.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"A\" (USD) ACC","LU1997245177.USD":"安联神洲A股基金","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU1808992512.USD":"AB ALL CHINA EQUITY PORTFOLIO \"A\" (USD) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK0216":"研究试验","LU1979443071.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"AD\" (USDHDG) INC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC"},"translate_title":"药明康德继续看好第三季度盈利超出预期——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603259":0.9},"content_text":"0402 GMT - WuXi AppTec keeps its bull at Nomura after its 3Q profit beat analysts' consensus estimate. The Chinese pharmaceutical services company raised its 2025 revenue and plans to spend less on capital expenditure, analyst Jialin Zhang says in a note. The company also agreed to sell its Chinese clinical research services unit, he says. The analyst raised his 2025 and 2026 earnings projections by 33.5% and 33.3%, respectively, to reflect factors such as enhanced efficiency and the unit disposal. Nomura reaffirms its buy rating and raises its target on WuXi AppTec's Hong Kong stock to HK$130.63 from HK$102.77. Nomura also raises its target on its Shanghai-listed shares to CNY118.83 from CNY93.49. Shares were last at HK$114.30 in Hong Kong and CNY105.73 in China. (megan.cheah@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 28, 2025 00:02 ET (04:02 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2578760091","isCrawlerRequest":true}